COMMUNIQUÉS West-GlobeNewswire

Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
07/03/2024
STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from [...]
Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference
07/03/2024
NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for [...]
Manitoba Harvest Hemp Foods Introduces Protein-Rich Breakfast Staples With New Superseed Instant Oatmeal
07/03/2024
Global Hemp Food Leader, Manitoba Harvest, Launches New Superseed Instant Oatmeal in Three Delicious Flavors Packed with Plant-Based Protein, Fiber, and Omegas to Help Fuel Your Mornings NEW YORK and WINNIPEG, Manitoba [...]
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
07/03/2024
• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of 2024 • FHD-909, a first-in-class BRM selective inhibitor, selected for clinical development by [...]
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
07/03/2024
– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieving all primary and secondary endpoints; initiation of the first Phase 3 clinical trial expected in 2H [...]
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results
07/03/2024
Q4 Revenues of $28.2 million Q4 Gross Margin of 58.0% (230 bps year-over-year improvement) Q4 operating income of $0.3 million, adjusted operating income of $ 3.3 million Strong operating cash flow enabled 2023 debt [...]
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
07/03/2024
On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of 2024 and Phase 1 data with NMRA-266 in healthy adult participants mid-2024 Strong financial position with $ [...]
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
07/03/2024
Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis (MG) remains on track for mid-2024 On track to initiate Phase 2 study of Descartes- [...]
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
07/03/2024
– Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first half of 2024 – – WTX-124 recommended dose for expansion (RDE), initiation of [...]
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
07/03/2024
CHARLESTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a non- [...]
LSL Pharma Group Announces a Combination of Private Placements for Maximum Aggregate Gross Proceeds of $8 Million
07/03/2024
Up to $3.5 M in cash proceeds Up to $4.5 M in debts conversion Proceeds to be used to further expand production capacity BOUCHERVILLE, Québec, March 07, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC . (TSXV: LSL) (the [...]
Le groupe LSL Pharma annonce une combinaison de placements privés pour un produit brut total maximum de 8 millions $
07/03/2024
Jusqu’à 3,5 millions $ de produits en espèces Jusqu'à 4,5 millions $ en conversion de dettes Les produits du financement serviront à augmenter la capacité de production BOUCHERVILLE, Québec, 07 mars 2024 (GLOBE NEWSWIRE [...]
Malaysia Makes Historic Debut in World's Best Hospitals 2024 by Newsweek
07/03/2024
Solidifying Its Position as a Leading Medical Tourism Hub KUALA LUMPUR, Malaysia, March 07, 2024 (GLOBE NEWSWIRE) -- In a monumental achievement for the nation, two Malaysian hospitals have been recognised in the highly [...]
BioNTech Announces Planned Retirement of Sean Marett
07/03/2024
Mainz, Germany, March 7, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Sean Marett, Chief Business and Commercial Officer, will retire as planned from the [...]
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
07/03/2024
Highlights: Immuron proceeding to Phase 3 registration strategy with the FDA Travelan® topline clinical trial results demonstrate protective efficacy with single daily dose 36.4% protective efficacy against [...]
Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024
07/03/2024
OGAP ® -Verify allows for significantly enhanced sensitivity and specificity for improved target selection, dramatically accelerating drug target discovery OGAP-Verify is now more sensitive than Immunohistochemistry ( [...]
MitoRx Therapeutics Strengthens Scientific Advisory Board with Appointment of Four International Experts
07/03/2024
Company is advancing mitochondriotropic therapeutic pipeline for rare neuromuscular disorders and neurodegenerative diseases OXFORD, United Kingdom, March 07, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a [...]
Nexstim Plc: Invitation to the Annual General Meeting
07/03/2024
Company announcement, Helsinki, 7 March 2024 at 10 AM (EET) Nexstim Plc: Invitation to the Annual General Meeting Nexstim Plc (NXTMH:HEX) (“Nexstim” or the “Company”) is pleased to invite shareholders to the Annual [...]
Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain
07/03/2024
Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain London, UK, 07 March 2024 – Persica Pharmaceuticals Ltd, a privately held, clinical stage [...]

Pages